Nemekhbayar Baatartsogt

Shimotsuke, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

High Prevalence of Preexisting Neutralizing Antibodies Against Adeno-Associated Virus Capsids in Mongolian People with Hemophilia.

High Prevalence of Preexisting Neutralizing Antibodies Against Adeno-Associated Virus Capsids in Mongolian People with Hemophilia.

Journal: Human gene therapy

Published: July 27, 2026

Nonviral delivery of a base editor enables personalized correction of hemophilia B nonsense variants in a mouse model.

Nonviral delivery of a base editor enables personalized correction of hemophilia B nonsense variants in a mouse model.

Journal: Journal of thrombosis and haemostasis : JTH

Published: November 10, 2025

Manufacture of adeno-associated virus vectors by a novel human-derived cell line HAT and comprehensive evaluation of the vectors.

Manufacture of adeno-associated virus vectors by a novel human-derived cell line HAT and comprehensive evaluation of the vectors.

Journal: Molecular therapy. Advances

Published: September 03, 2025

Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy.

Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy.

Journal: Blood

Published: January 17, 2025

The factor (F)VIII K1693N mutation (FVIII-Nara) in a patient with moderate hemophilia A confers resistance to thrombin-catalyzed cleavage at Arg1689 involving P4' position.

The factor (F)VIII K1693N mutation (FVIII-Nara) in a patient with moderate hemophilia A confers resistance to thrombin-catalyzed cleavage at Arg1689 involving P4' position.

Journal: Journal of thrombosis and haemostasis : JTH

Published: December 10, 2024

Therapeutic base editing to generate a gain-of-function F9 variant for hemophilia B.

Therapeutic base editing to generate a gain-of-function F9 variant for hemophilia B.

Journal: Blood

Published: November 30, 2024

Cure of Congenital Purpura Fulminans via Expression of Engineered Protein C Through Neonatal Genome Editing in Mice.

Cure of Congenital Purpura Fulminans via Expression of Engineered Protein C Through Neonatal Genome Editing in Mice.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: November 07, 2024

The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential.

The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential.

Journal: Blood advances

Published: December 12, 2023

Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A.

Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A.

Journal: Blood advances

Published: May 30, 2023

Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy.

Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy.

Journal: Molecular therapy. Methods & clinical development

Published: February 17, 2023

Successful liver transduction by re-administration of different adeno-associated virus vector serotypes in mice.

Successful liver transduction by re-administration of different adeno-associated virus vector serotypes in mice.

Journal: The journal of gene medicine

Published: October 23, 2022

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs.

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs.

Journal: Molecular therapy. Methods & clinical development

Published: June 21, 2022

Showing 1-12 of 16

Last Updated: 09/26/2026